Skip to main content
DaehanPharmaceutical logo

DaehanPharmaceutical — Investor Relations & Filings

Ticker · 023910 ISIN · KR7023910003 KO Manufacturing
Open in API
Filings indexed 297 across all filing types
Latest filing 2025-03-18 Annual Report
Country KR South Korea
Listing KO 023910

About DaehanPharmaceutical

https://www.dhnp.co.kr/

Daehan Nupharm is a pharmaceutical company engaged in the research, development, and manufacturing of a diverse portfolio of healthcare products. The company's business is structured around four core areas: human pharmaceuticals, offering a range of therapeutic treatments; animal health products for both companion and livestock animals; advanced bio-pharmaceuticals, with a focus on next-generation technologies like cell therapy; and health functional foods. Established initially in the animal health sector, the company leverages its dedicated Central and Bio Research Institutes to drive innovation and develop solutions for global markets. The R&D efforts concentrate on strengthening technological capabilities and advancing new treatment modalities.

Recent filings

Filing Released Lang Actions
사업보고서 (2024.12)
Annual Report Classification · 1% confidence The document is a 'Business Report' (사업보고서) for Daihan Pharmaceutical Co., Ltd. (대한약품공업주식회사) for the 61st fiscal year (2024). It contains comprehensive financial information, management discussion, governance details, and audit information, which is the standard format for an Annual Report in the South Korean regulatory context (DART). It is not an announcement of a report, but the report itself. FY 2024
2025-03-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Lee Yoon-woo) of Daehan Pharmaceutical Co., Ltd. It details changes in share ownership due to market purchases. In the context of financial filings, reports regarding personal share transactions by company directors and executives are classified as 'Director's Dealing'.
2025-03-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details share transactions (purchases) made by an executive (Lee Seung-young) of Daehan Pharmaceutical Co., Ltd. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2025-03-13 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of Convocation of the Annual General Meeting' (주주총회소집공고) for Daihan Pharm Co., Ltd. It contains the meeting agenda, date, location, voting procedures, and detailed financial statements (balance sheet, income statement, etc.) to be approved by shareholders. This is a standard proxy statement and meeting notice package provided to shareholders to inform them of the upcoming AGM and request their votes. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2025-03-07 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (equivalent to a Proxy Statement) used to solicit shareholder votes for an upcoming Annual General Meeting. It contains information about the meeting agenda, board proposals, and financial statements to be approved. This fits the definition of a Proxy Solicitation & Information Statement (PSI).
2025-03-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details share transactions (장내매수 - open market purchases) by a company executive (Lee Yoon-woo) of Daehan Pharmaceutical Co., Ltd. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2025-03-06 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.